MeiraGTx Holdings PLC Total Liabilities

Latest as of June 2026: $180.67 Million USD

MeiraGTx Holdings PLC total liabilities. Based on the latest financial reports, MeiraGTx Holdings PLC (MGTX) has total liabilities worth $180.67 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check MGTX financial resilience to evaluate the company's liquid asset resilience ratio.

Total Liabilities of MeiraGTx Holdings PLC (2016–2025)

Total liabilities of MeiraGTx Holdings PLC from 2016 to 2025. This chart illustrates how MeiraGTx Holdings PLC's total liabilities have evolved over time, based on quarterly financial data. Explore MeiraGTx Holdings PLC long-term investment intensity to see how much of total assets are deployed in long-term investments.

MeiraGTx Holdings PLC Competitors by Total Liabilities

The table below lists competitors of MeiraGTx Holdings PLC ranked by their total liabilities.

Company Country Total Liabilities
Shunfa Hengye Corp
SHE:000631
China CN¥1.72 Billion
Macquarie Technology Group Ltd
AU:MAQ
Australia AU$292.18 Million
Svenska Handelsbanken AB (publ)
ST:SHB-B
Sweden Skr3.69 Trillion
Upbound Group Inc.
NASDAQ:UPBD
USA $2.37 Billion
Shenzhen MYS Environmental Protection & Technology Co Ltd
SHE:002303
China CN¥2.73 Billion
Amata Corporation Public Company Limited
BK:AMATA
Thailand ฿41.57 Billion
Wuxi Xinhongye Wire & Cable Co. Ltd. A
SHE:301310
China CN¥3.36 Billion
Beijing Jingwei Hirain Technologies Co. Ltd. A
SHG:688326
China CN¥6.00 Billion

Liability Composition Analysis (2016–2025)

This chart breaks down MeiraGTx Holdings PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see MeiraGTx Holdings PLC asset portfolio.

Liquidity & Leverage Metrics

MeiraGTx Holdings PLC Total Liabilities Ratios Explained

MeiraGTx Holdings PLC total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 3.76 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.84 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.46 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how MeiraGTx Holdings PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for MeiraGTx Holdings PLC (2016–2025)

The table below shows the annual total liabilities of MeiraGTx Holdings PLC from 2016 to 2025.

Year Total Liabilities Change
2025-12-31 $250.22 Million +23.92%
2024-12-31 $201.92 Million +7.08%
2023-12-31 $188.57 Million -5.95%
2022-12-31 $200.50 Million +48.78%
2021-12-31 $134.76 Million +7.69%
2020-12-31 $125.14 Million -5.97%
2019-12-31 $133.09 Million +740.44%
2018-12-31 $15.84 Million -78.37%
2017-12-31 $73.22 Million +84.48%
2016-12-31 $39.69 Million --

About MeiraGTx Holdings PLC

NASDAQ:MGTX USA Biotechnology
Market Cap
$914.33 Million
Market Cap Rank
#8931 Global
#2557 in USA
Share Price
$9.52
Change (1 day)
+2.15%
52-Week Range
$6.99 - $14.97
All Time High
$30.01
About

MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia. It is also develops AAV-AQP1 for radiation-induced grade 2/3 radiation-induced xe… Read more